FMP
CureVac Review, Focusing on 2nd-Gen COVID Vaccine
Dec 17, 2021 4:36 PM - Davit Kirakosyan(Last modified: Dec 19, 2023 6:49 PM)
Image credit: FMP
Analysts at Berenberg Bank provided their outlook on CureVac N.V. (NASDAQ:CVAC), mentioning that they believe the withdrawal of first-generation CVnCoV from the approval process effectively removes an overhang from the stock.
According to the analysts, they like the potential of the GlaxoSmithKline (GSK) partnered second-generation COVID-19 vaccine (CV2CoV) and believe it has the potential to capture what they expect will be an active booster market given the virus likely continues to mutate; the emergence of the omicron variant being a prime example of this.
Other Blogs
May 14, 2024 11:41 AM - Sanzhi Kobzhan
The easiest way to calculate stock’s target price and why the target price is important.
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
How to Access and Analyze Earnings Call Transcripts
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
The best 5 GPU stocks other than NVDA
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...
